Cialis (Tadalafil) Pregnancy & Lactation Safety

How Tadalafil Works: The PDE5 Mechanism Relevant to Pregnancy

Tadalafil selectively inhibits phosphodiesterase type 5 (PDE5), the enzyme that degrades cyclic guanosine monophosphate (cGMP) in smooth muscle cells. When PDE5 is blocked, cGMP accumulates, activating protein kinase G, reducing intracellular calcium, and causing vascular smooth muscle relaxation. This mechanism lowers pulmonary vascular resistance in PAH and relaxes penile corpus cavernosum smooth muscle in erectile dysfunction.

Understanding this pathway matters in pregnancy because PDE5 is not confined to penile or pulmonary tissue.

PDE5 Distribution in Reproductive Tissue

PDE5 is expressed in the human myometrium, placental vasculature, and umbilical vessels. A study published in Molecular Human Reproduction confirmed PDE5 protein expression across gestational ages in placental trophoblasts and villous stroma. [1] That expression raises the question of whether pharmacological PDE5 blockade alters uteroplacental blood flow or uterine contractility at term.

Nitric oxide (NO) generated by endothelial nitric oxide synthase (eNOS) drives cGMP synthesis via guanylate cyclase. During normal pregnancy, eNOS activity rises substantially, contributing to the systemic vasodilation that lowers maternal mean arterial pressure by roughly 10 mmHg in the second trimester. [2] Superimposing a PDE5 inhibitor on an already-vasodilated system could theoretically exaggerate hypotension, reduce uteroplacental perfusion pressure, or both.

Duration of Action Compared With Other PDE5 Inhibitors

Tadalafil's plasma half-life of approximately 17.5 hours is roughly four times longer than sildenafil's 3-to-5-hour half-life. [3] That pharmacokinetic difference means any fetal exposure from a maternal dose persists for the better part of a day. Sildenafil has been studied more extensively in obstetric contexts (including the ill-fated STRIDER trial discussed below), so tadalafil's longer half-life and distinct metabolism via CYP3A4 make direct extrapolation from sildenafil data unreliable.

FDA Regulatory Status and the 2015 PLLR Rule

Before June 2015, tadalafil carried an FDA Pregnancy Category B designation based on animal data showing no clear teratogenicity at doses below the toxic threshold. The Pregnancy and Lactation Labeling Rule (PLLR), effective June 30, 2015, eliminated letter categories for drugs first approved after June 2001. [4] Tadalafil (approved 2003) therefore falls under PLLR narrative labeling.

What the Current Label Actually States

The current FDA-approved prescribing information for Adcirca (tadalafil 20 mg, the PAH formulation) states under Section 8.1:

"Available data from published literature and postmarketing experience with tadalafil use in pregnant women are insufficient to identify a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes."

The label further notes that animal reproduction studies showed adverse developmental effects at exposures several times the maximum recommended human dose (MRHD). [5] The FDA's reproductive toxicology summary for tadalafil on Drugs@FDA remains the primary regulatory reference clinicians should consult before any off-label prescribing in pregnancy. [5]

Animal Reproductive Toxicology

In Sprague-Dawley rat studies submitted for FDA approval, doses of 1,000 mg/kg/day produced reduced fetal body weight and delayed skeletal ossification. No external or visceral structural malformations occurred at those doses. The no-observed-adverse-effect level (NOAEL) for developmental toxicity was 200 mg/kg/day, yielding an estimated safety margin roughly 32-fold above the human 40 mg/day PAH dose on an area-under-the-curve (AUC) basis. [5]

Rabbit studies at 100 mg/kg/day showed no fetal malformations, though maternal toxicity (reduced food intake, weight loss) was present at the highest doses, complicating interpretation of the embryo-fetal data. [5]

Animal data are necessary but not sufficient for predicting human teratogenicity. Thalidomide caused no harm in rats yet was catastrophic in humans. Conversely, drugs that harm rat fetuses at supratherapeutic doses often prove safe in humans. The animal data for tadalafil are reassuring at clinically relevant exposures but cannot rule out low-frequency human teratogenicity.

Human Pregnancy Data: PAH Cohorts and Case Reports

No randomized controlled trial has evaluated tadalafil in human pregnancy. All available data come from PAH registries, retrospective cohorts, and case reports.

The PAH-in-Pregnancy Problem

Pulmonary arterial hypertension in pregnancy carries a maternal mortality risk estimated at 16-to-30% in contemporary registries, down from historical figures exceeding 50% but still among the highest of any cardiac condition in pregnancy. [6] The 2022 ESC Guidelines on Cardiovascular Disease in Pregnancy give PAH a Class III recommendation (harm) for pregnancy itself, meaning the guideline authors recommend against pregnancy in women with PAH. [6]

Yet some women with PAH become pregnant despite counseling, and others decline termination. In those cases, continuing PAH-targeted therapy is often the least harmful option. Tadalafil, sildenafil, and inhaled iloprost are the agents most commonly continued.

Published Case Series and Registry Data

A 2014 analysis in Chest reviewed 18 pregnancies in women with PAH maintained on various vasodilator therapies including PDE5 inhibitors. Maternal survival was 89% with aggressive multidisciplinary management, though preterm birth occurred in 72% of continuing pregnancies. [7] Tadalafil was used in a subset of those patients, but the small numbers preclude drug-specific conclusions.

The COMPERA registry (Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension), which tracks real-world PAH treatment patterns across European centers, has published aggregate survival data but has not released a pregnancy-specific tadalafil sub-analysis as of this review. [8]

A 2020 case report in Pulmonary Circulation described a woman maintained on tadalafil 40 mg/day through 34 weeks gestation who delivered a viable infant without structural anomalies, though the neonate required NICU admission for respiratory support. [9] Single case reports cannot establish safety, but they contribute to the totality of evidence.

The STRIDER Trial Cautionary Note

The Sildenafil Therapy In Dismal prognosis Early-onset intrauterine growth Restriction (STRIDER) trial used sildenafil, not tadalafil, to treat fetal growth restriction. The Netherlands arm was halted early after increased neonatal pulmonary hypertension deaths in the sildenafil group (19 deaths vs. 9 in placebo, P<0.05). [10] The trial targeted fetal growth restriction rather than maternal PAH, but the signal is biologically relevant to tadalafil because both drugs share the PDE5 mechanism.

The proposed mechanism of harm was persistent pulmonary hypertension of the newborn (PPHN): sildenafil crossed the placenta, maintained fetal pulmonary vasodilation in utero, and when the neonatal pulmonary circuit was expected to constrict then rapidly vasodilate at birth, the pharmacological interference disrupted that transition. Tadalafil's longer half-life could theoretically prolong that risk window compared with sildenafil.

Placental Transfer and Fetal Pharmacology

Evidence for Placental Crossing

Direct human data on tadalafil placental transfer are sparse. An ex-vivo human placental perfusion study published in Reproductive Toxicology found that tadalafil transferred across the placenta with a fetal-to-maternal concentration ratio of approximately 0.23 at steady state, lower than sildenafil's ratio of roughly 0.38 in similar models. [11] A ratio below 1.0 indicates partial but not complete equilibration; the fetus still receives meaningful drug exposure.

Fetal PDE5 Physiology

Before birth, the fetal pulmonary circulation is maintained in a state of high resistance by low oxygen tension and endogenous vasoconstrictors. At birth, oxygen exposure triggers NO release and cGMP accumulation, driving rapid pulmonary vasodilation. Exogenous PDE5 inhibition can disrupt this tightly regulated transition. [12] The STRIDER signal makes this pathway a legitimate concern for any PDE5 inhibitor used near term, including tadalafil.

Neonatologists use inhaled nitric oxide and sometimes oral sildenafil to treat PPHN postnatally. The irony is that while PDE5 inhibitors treat PPHN after birth, in-utero exposure may contribute to it, likely by desensitizing the pulmonary cGMP pathway through chronic inhibition.

Tadalafil and Uterine Contractility

A small but important body of bench research suggests PDE5 inhibitors may relax uterine smooth muscle, because the myometrium expresses both PDE5 and soluble guanylate cyclase. A 2011 study in Reproductive Sciences showed that sildenafil reduced oxytocin-stimulated myometrial contractions in ex-vivo strip preparations from term human uterus. [13] Whether tadalafil produces the same effect at clinical doses in vivo is unknown.

If tadalafil reduces myometrial contractility at term, it could theoretically prolong labor or increase the risk of postpartum hemorrhage. No clinical data confirm or refute this concern specifically for tadalafil in human pregnancy.

Lactation: What the Data Do and Do Not Show

Absence of Human Milk Pharmacokinetic Data

No published pharmacokinetic study has measured tadalafil concentrations in human breast milk. The manufacturer's labeling states that tadalafil is present in rat milk but provides no human lactation data. [5] The LactMed database maintained by the National Library of Medicine similarly notes the absence of human milk data and advises that an alternate drug should be considered if lactation is desired. [14]

Estimating Infant Exposure

Without measured milk concentrations, clinicians sometimes use protein binding and lipophilicity to estimate relative infant dose. Tadalafil is approximately 94% protein-bound and has a moderate lipophilicity (log P ~1.4). High protein binding generally limits transfer into milk, but the drug's long half-life means that even small milk concentrations would result in prolonged infant exposure with each feeding cycle.

A theoretical relative infant dose calculation using the highest reported maternal plasma Cmax (378 ng/mL after 40 mg) and an assumed milk-to-plasma ratio of 0.5 (conservative estimate for a moderately lipophilic, high-protein-bound drug) yields an estimated infant dose of roughly 2.8 mcg/kg/day, well below the 10% threshold commonly used to flag lactation risk. [15] That calculation is speculative. It relies on an assumed milk-to-plasma ratio that has not been measured. Clinical decisions should not rest on theoretical estimates alone.

Practical Guidance for Breastfeeding Patients

Women taking tadalafil 40 mg/day for PAH who wish to breastfeed face a choice between a drug with unknown but potentially low milk transfer and complete formula feeding. The decision depends on disease severity, neonatal prematurity status, and the availability of wet nurses or donor milk. Pump-and-discard strategies are less useful for a drug with a 17.5-hour half-life than for shorter-acting medications.

The Academy of Breastfeeding Medicine and the WHO both support breastfeeding as the default recommendation for infants of mothers on medications, but both organizations also require that the benefit-risk calculation account for the specific drug's profile. [16] For tadalafil, that profile currently lacks the human data needed to make a strong evidence-based recommendation either way.

Clinical Decision Framework for Prescribers

Women of Reproductive Age Prescribed Tadalafil for PAH

Any woman of reproductive potential starting tadalafil for PAH should receive counseling that covers three points: the high maternal mortality risk of PAH in pregnancy (16-30%), the absence of proven safe dosing in human pregnancy, and the need for reliable contraception. [6] The 2022 ESC/ERS pulmonary hypertension guidelines recommend shared decision-making with a specialized PAH center before any pregnancy attempt. [17]

Women Who Present Already Pregnant

If a woman with PAH is already pregnant and currently taking tadalafil, abrupt discontinuation risks pulmonary hypertensive crisis. The calculus shifts toward continuing therapy under close surveillance at a maternal-fetal medicine and PAH center. Delivery planning should target 34-to-36 weeks to balance neonatal maturity against maternal hemodynamic risk, and the neonatal team must be briefed on the theoretical PPHN risk from in-utero PDE5 inhibitor exposure.

Tadalafil for Erectile Dysfunction or BPH in Male Partners

Male patients using tadalafil for erectile dysfunction or benign prostatic hyperplasia (BPH) do not expose their pregnant partners to tadalafil through seminal fluid in clinically meaningful concentrations. Seminal plasma tadalafil concentrations are low, and the volume of ejaculate relative to maternal plasma volume makes systemic absorption by the partner negligible. This point is sometimes raised by anxious couples; reassurance is appropriate.

Drug Interactions That Complicate Pregnancy Use

Tadalafil is metabolized primarily by CYP3A4. Pregnancy alters CYP3A4 activity, with some data suggesting induction in the second and third trimesters, which could reduce tadalafil plasma concentrations by 20-to-40% compared with non-pregnant steady state. [18] That pharmacokinetic shift matters for PAH patients, where inadequate drug exposure could allow pulmonary vascular resistance to rise.

Drugs commonly used in obstetric settings that interact with tadalafil include:

• Nitrates (absolutely contraindicated with tadalafil due to severe hypotension risk)
• Azole antifungals (fluconazole, ketoconazole) raise tadalafil AUC by up to 2-fold via CYP3A4 inhibition [3]
• Rifampicin (used occasionally for obstetric cholestasis) reduces tadalafil AUC by approximately 88% [3]
• Magnesium sulfate (used for preeclampsia and tocolysis) has additive vasodilatory effects; blood pressure monitoring is warranted

Monitoring Parameters in Pregnant PAH Patients on Tadalafil

Patients who continue tadalafil through pregnancy should have:

• Right heart catheterization or echocardiographic assessment of pulmonary artery pressures each trimester
• Maternal blood pressure monitoring at each antenatal visit given the additive vasodilatory effect of pregnancy plus tadalafil
• Fetal growth ultrasound every 4 weeks starting at 24 weeks, given theoretical concerns about uteroplacental perfusion
• Neonatal echocardiogram in the first 24-to-48 hours of life to screen for PPHN, based on the mechanistic signal from the STRIDER trial [10]

The 2022 ESC cardiovascular guidelines specify that women with PAH who continue pregnancy should be managed at expert centers with co-located cardiac surgery, neonatology, and obstetric anesthesia capability. [6]